Astellas Pharma Inc.

ALPMF · OTC
Analyze with AI
3/31/2025
3/31/2024
3/31/2023
3/31/2022
Operating Activities
Net Income$31$17$132$157
Dep. & Amort.$199$158$106$80
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC-$166-$87-$24$6
Other Non-Cash$131$84$114$15
Operating Cash Flow$195$172$328$257
Investing Activities
PP&E Inv.-$37-$38-$89-$76
Net Acquisitions$0-$785$0-$1
Inv. Purchases$0$0$0-$6
Inv. Sales/Matur.$13$0$13$6
Other Inv. Act.-$65-$23-$9$15
Investing Cash Flow-$89-$846-$85-$62
Financing Activities
Debt Repay.-$89$771-$15-$60
Stock Issued$0$0$0$0
Stock Repurch.-$7-$11-$61-$51
Dividends Paid-$129-$117-$100-$85
Other Fin. Act.-$37-$30-$20-$20
Financing Cash Flow-$261$614-$196-$216
Forex Effect$9$18$13$11
Net Chg. in Cash-$147-$41$61-$10
Supplemental Information
Beg. Cash$336$377$316$326
End Cash$188$336$377$316
Free Cash Flow$137$90$239$181
Astellas Pharma Inc. (ALPMF) Financial Statements & Key Stats | AlphaPilot